Myriad Genetics reported a 23% increase in third-quarter revenue to $191.9 million, driven by strong growth in testing volumes. The company raised its 2023 revenue guidance and introduced 2024 revenue guidance, reflecting confidence in its growth trajectory.
Third quarter testing volume grew 18% year-over-year, excluding contributions from the SneakPeek® Early Gender DNA Test, marking the fifth consecutive quarter of double-digit growth.
Third quarter revenue increased by 23% year-over-year to $191.9 million, inclusive of a $7.1 million change of estimate.
GAAP gross margin for the third quarter was 70.0%, showing an increase of 221 basis points compared to the same period in 2022.
The company increased its 2023 revenue guidance to between $747 million and $753 million, indicating a growth of 10% - 11% over 2022.
Myriad Genetics provided revenue guidance for 2023 and 2024.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance